Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,877 people get CTIC articles and Market Currents by email alert.
Get email alerts on CTIC »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
-
-
More Drama From Cell TherapeuticsM. E. Garza • Mon, Jan 30, 2012 -
-
-
-
-
Cell Therapeutics: FDA Approves Italian FactoryZacks Investment Research • Tue, Mar 9, 2010
-
-
-
-
-
-
Cell Therapeutics Starts Phase III Lung Cancer TrialSA Editor Susan Lerner • Mon, Sep 24, 2007
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
Today's Market News To Trade On: 5 Stocks Moving On NewsMatthew Smith • Wed, Sep 12, 2012 -
-
-
-
-
-
-
-
-
-
-
Cell Therapeutics' CEO Hosts Annual Shareholder Meeting (Transcript)Fri, Aug 31, 2012
-
Cell Therapeutics, Inc. Q1 2010 Earnings Call TranscriptWed, Apr 28, 2010
-
Cell Therapeutics, Inc. Q2 2008 Earnings Call TranscriptMon, Aug 18, 2008
-
PR Newswire (Mon, 1:00AM)
-
PR Newswire (Jun 11, 2013)
-
PR Newswire (May 20, 2013)
-
PR Newswire (May 15, 2013)
-
PR Newswire (May 2, 2013)
-
PR Newswire (Apr 24, 2013)
-
PR Newswire (Apr 10, 2013)
-
PR Newswire (Mar 28, 2013)
-
PR Newswire (Mar 11, 2013)
-
PR Newswire (Mar 4, 2013)
-
PR Newswire (Feb 28, 2013)
CTIC vs. ETF Alternatives
Company Description
We develop, acquire and commercialize novel treatments for cancer. Our goal is to build a leading biopharmaceutical company with a diversified portfolio of proprietary cancer drugs. Our research and in-licensing activities are concentrated on identifying new, less toxic and more effective ways... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Tuesday, May 21, 2:21 PM Shares of Cell Therapeutics (CTIC +6.5%) spike higher ahead of today's upcoming presentation at the UBS Global Healthcare Conference. The presentation will be held at 2:30 ET and is accessible on webcast here: [[CTIC} Presentation Webcast}. Comment! [Healthcare, On the Move]
-
Monday, May 6, 9:12 AM
Premarket gainers: CBMX +8%. YRCW +7%. APO +7%. CTIC +6%.
Losers: PAL -12%. LNCO -7%. LINE -6%. 12 Comments [On the Move] - Thursday, March 28, 11:06 AM Cell Therapeutics (CTIC +12.5%) trades higher today after securing a loan agreement with Hercules Technology Growth Capital for a senior secured term loan of up to $15M. The proceeds are intended to provide additional operating capital to advance Phase 3 clinical studies of pacritinib, its treatment for patients with myelofibrosis, and driving the adoption of Pixuvri in Europe . 1 Comment [Healthcare, On the Move]
-
Thursday, March 28, 9:10 AM
Premarket gainers: RPRX +75%. CTIC +14%. ONCY +8%. EXM +7%. DECK +6%. XONE +6%.
Losers: TWO -8%. FIVE -7%. GME -5%. 1 Comment [On the Move] -
Tuesday, March 26, 9:15 AM
Premarket gainers: THLD +8%. CTIC +6%.
Losers: ZIOP -62%. PLCE -6%. PATH -6%. Comment! [On the Move] - Wednesday, January 9, 2:24 PM After rising nearly 25% yesterday on big volume, shares of Cell Therapeutics (CTIC -11%) give back a big chunk today. The stock has been volatile over the past few sessions, largely trading in tandem with big moves in competitor Peregrine Pharmaceuticals (PPHM -11%), who announced favorable news on Mondary of its review of data on its experimental cancer drug bavituximab, saying it wasn't comprimised. 1 Comment [Healthcare, On the Move]
-
Wednesday, January 9, 12:45 PM
Midday top 10 gainers: ININ +19%. KGJI +15%. SINO +14%. ZIPR +14%. CTC +14%. ROSG +13%. CSIQ +13%. TSL +13%. SAAS +12%. SMED +12%.
Midday top 10 Losers: SCHS -29%. PPHM -12%. PTEK -11%. CTIC -11%. DLGC -11%. MG -11%. ZA -10%. DYSL -9%. APOL -9%. CRK -8%. Comment! [On the Move] - Tuesday, January 8, 10:10 AM Cell Therapeutics (CTIC) rockets 24%, although it's hard to work out why. The stock's been fairly volatile over the past few months, and often seems to receive a big lift on news of Pixuvri, its treatment of aggressive non-Hodgkin B-cell lymphomas. 3 Comments [On the Move, Healthcare]
-
Tuesday, January 8, 9:10 AM
Premarket gainers: PERI +19%. STSI +16%. CTIC +8%. PPHM +5%.
Losers: GME -10%. APPY -6%. CY -6%. CLMT -5%. Comment! [On the Move] - Monday, December 17, 2012, 3:47 PM Cell Therapeutics (CTIC +2.8%) moves higher today after publishing positive results from a pre-clinical study of Pixuvri in The Journal of Pharmacology and Experimental Therapeutics. The study showed that in a human cardiac tissue model treated with Pixuvri did not form reactive oxygen species or long lived hydroxymetabolites. Additionally, the drug inhibited formation of the long-lived hydroxymetabolite of doxorubicin, which suggests a low incidence of cardiotoxicity. Comment! [Healthcare, On the Move]
-
Monday, December 17, 2012, 9:10 AM
Premarket gainers: JVA +12%. ENZN +10%. CBMX +10%. LXRX +9%. TROX +6%. CTIC +5%.
Losers: NBG -13%. CLWR -11%. SQNM -6%. Comment! [On the Move] - Monday, December 10, 2012, 3:24 PM Cell Therapeutics (CTIC -5.9%) dips today after its Board of Directors approves amendments to CTI's existing shareholder rights plan to decrease the exercise price of the preferred stock purchase rights from $14.00 to $8.00 and to extend the final expiration date from January 7, 2010, to December 3, 2015. The Rights were initially distributed as a dividend on CTI's common stock. 1 Comment [Healthcare, On the Move]
-
Monday, October 15, 2012, 9:10 AM
Premarket gainers: YONG +15%. CLWR +14%. EDU +14%. AEGR +14%. CEL +9%. MTSL +8%. CTIC +8%. ISIS +7%.
Losers: DCTH -12%. 1 Comment [On the Move] -
Friday, October 12, 2012, 9:10 AM
Premarket gainers: NPSP +11%. CTIC +9%. STM +8%.
Losers: AEZS -24%. AMD -11%. INFY -7%. 1 Comment [On the Move] - Friday, October 12, 2012, 9:07 AM Cell Therapeutics (CTIC) up 8.5% premarket as it announces the closing of its $60M convertible preferred stock offering. The company got about $55.6M after expenses; each share of the Series 17 Preferred is convertible into about 714 shares of common stock at a $1.40/share conversion price. (previously) 2 Comments [Healthcare, On the Move]
-
Friday, October 5, 2012, 9:10 AM
Premarket gainers: PPP +26%. ATHX +9%.
Losers: CTIC -28%. ZNGA -20%. VRNG -14%. ABR -5%. Comment! [On the Move]
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
freefdawatchlist
http://bit.ly/VaT4zl PREMARKET WATCH FOR OCT 2ND: Gainer: $CELG, $CTIC, Losers: $ARQL, $EXPR, $GEL,$SFL - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 2 replies
-
trustgus: It's only at 0.42. 5:1 reverse stock split. That's about .04 off its 52 week low.
-
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES
-
- View all 2 replies
-
trustgus: It's only at 0.42. 5:1 reverse stock split. That's about .04 off its 52 week low.
-
-
- View all 6 replies
-
-
-
- View all 3 replies
-
freefdawatchlist: don't buy more, because if fda delay it by 3 month, the stock may drop. Check out other stock which haven't rallied up till now.
-
-
- View all 1 replies
-
